Drugs / RO5267683
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01398241 | Aug 2011 → Jun 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5267683 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01398241 ↗ |
| Route | Oral | “Subjects will be randomized to receive either RO5267683 or placebo orally daily for 28 days.” NCT01398241 ↗ |